The analyses performed in this study to further determine the differences between brigatinib and alectinib’s mechanisms of action point towards a potentially relevant role of RET, EFGR, IGF1R and FLT3 (besides ALK) in treating NSCLC. Here, IGF1R is linked to non-small cell lung carcinoma.